Program
Nivolumab
Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 12410 open or running | phase 4since Nov 2, 2015 | Feb 27, 2007 | Feb 5, 2027phase 2 · NCT06946797 |
| Ono Pharmaceutical | 144 open or running | phase 3since Oct 9, 2014 | Jan 26, 2009 | Dec 31, 2027phase 2 · NCT04566380 |
| Pfizer | 20 open or running | phase 2since Oct 7, 2015 | Oct 7, 2015 | none ahead |
| ella-therapeutics-ltd | 10 open or running | phase 2since Aug 13, 2020 | Aug 13, 2020 | none ahead |
| excellabio-llc | 10 open or running | phase 2since Oct 20, 2017 | Oct 20, 2017 | none ahead |
| nilogen-oncosystems | 10 open or running | early phase 1since Dec 3, 2017 | Dec 3, 2017 | none ahead |
| rampart-health-l-l-c | 10 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| USWM CT | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Halozyme Therapeutics, medarex, parexel, Astellas Pharma, akamis-bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Mar 28, 2017.
- Oct 6, 2021Phase 3 study in Stomach NeoplasmsOno Pharmaceutical · NCT05144854 · 626 enrolled · Japan, South Korea, Taiwan
- Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
- Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinBristol-Myers Squibb · NCT05255601 · 5 enrolled · United States, Australia, France and more
- Aug 9, 2022Phase 2 study in MelanomaBristol-Myers Squibb · NCT05496192 · Germany, Spain
- Aug 10, 2022Phase 1 study in Advanced Solid TumorsBristol-Myers Squibb · NCT05498480 · 6 enrolled · China
- Oct 26, 2022USWM CT's first study: phase 2 study in Ovarian NeoplasmsNew to USWM CTUSWM CT · NCT05601752 · 21 enrolled · United States, Canada, France and more
- Nov 15, 2022Phase 3 study in MelanomaBristol-Myers Squibb · NCT05625399 · 579 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 2 study in MelanomaBristol-Myers Squibb · NCT06101134 · 100 enrolled · United States, Chile, Greece and more
- Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06561386 · 1,000 planned · United States, Argentina, Australia and more
- Sep 30, 2024Phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941 · 23 planned · Japan
- Apr 13, 2025Phase 2 study in Richter's TransformationOno Pharmaceutical · NCT06936943 · 14 planned · Japan
- Apr 25, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797 · 76 enrolled · United States, Brazil, Chile and more
- Mar 5, 2026Phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543 · 40 planned · India
- Oct 14, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT04566380
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797
- Dec 31, 2027Primary completion: phase 2 study in Pan-tumorOno Pharmaceutical · NCT04566380
- Jan 31, 2029Primary completion: phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941
- May 26, 2029Primary completion: phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 145 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07459543Melanoma · India | 4 | Not yet recruiting | Bristol-Myers Squibb | May 26, 2029 | 40 |
| NCT06946797Carcinoma, Non-Small-Cell Lung · United States, Brazil, Chile and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Feb 5, 2027 | 76 |
| NCT06936943Richter's Transformation · Japan | 2 | Recruiting | Ono Pharmaceutical | Jul 31, 2029 | 14 |
| NCT06622941Rhabdoid Tumor · Japan | 2 | Recruiting | Ono Pharmaceutical | Jan 31, 2029 | 23 |
| NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jul 30, 2030 | 1,000 |
| NCT06101134Melanoma · United States, Chile, Greece and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Apr 10, 2025 | 100 |
| NCT05625399Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Aug 4, 2025 | 579 |
| NCT05601752Ovarian Neoplasms · United States, Canada, France and more | 2 | Terminated | USWM CT | Sep 30, 2025 | 21 |
| NCT05498480Advanced Solid Tumors · China | 1 | Completed | Bristol-Myers Squibb | Jan 18, 2024 | 6 |
| NCT05496192Melanoma · Germany, Spain | 2 | Withdrawn | Bristol-Myers Squibb | Jun 24, 2024 | 0 |
| NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more | 2 | Terminated | Bristol-Myers Squibb | Dec 3, 2025 | 5 |
| NCT05136677Mesothelioma, Malignant · China | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2025 | 102 |
| NCT05144854Stomach Neoplasms · Japan, South Korea, Taiwan | 3 | Active, not recruiting | Ono Pharmaceutical | Oct 20, 2025 | 626 |
| NCT04567615Carcinoma, Hepatocellular · Argentina, Brazil, Chile and more | 2 | Completed | Bristol-Myers Squibb | Aug 31, 2023 | 266 |
| NCT04566380Pan-tumor · Japan, South Korea, Taiwan | 2 | Recruiting | Ono Pharmaceutical | Dec 31, 2027 | 70 |
| NCT04521075Melanoma · Israel | 2 | UNKNOWN | ella-therapeutics-ltd | Jul 1, 2022 | 42 |
| NCT04513522Kidney Neoplasms · India | 4 | Completed | Bristol-Myers Squibb | Jan 4, 2024 | 101 |
| NCT04495010Melanoma · United States, Australia, Austria and more | 2 | Withdrawn | Bristol-Myers Squibb | Feb 28, 2024 | 0 |
| NCT04340193Liver Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Dec 12, 2023 | 26 |
| NCT04311710Neoplasms · United States, Italy, New Zealand | 1 | Terminated | Bristol-Myers Squibb | Jan 14, 2021 | 21 |
| NCT04209114Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jun 7, 2023 | 114 |
| NCT04151563Carcinoma · United States, Argentina, Belgium and more | 2 | Withdrawn | Bristol-Myers Squibb | Dec 17, 2023 | 0 |
| NCT04149574Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Bristol-Myers Squibb | Oct 31, 2023 | 13 |
| NCT04109066Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2023 | 521 |
| NCT04100018Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 1,030 |
| NCT04099251Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jun 28, 2022 | 790 |
| NCT04088500Carcinoma, Renal Cell · United States, Canada | 2 | Terminated | Bristol-Myers Squibb | Nov 15, 2021 | 5 |
| NCT04075604Breast Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Jul 27, 2021 | 23 |
| NCT04090775Metastatic Prostatic Adenocarcinoma · United States | 2 | Completed | rampart-health-l-l-c | Jul 30, 2020 | 12 |
| NCT04039607Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jul 9, 2026 | 732 |
| NCT04026412Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 22, 2024 | 925 |
| NCT04025879Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jul 26, 2023 | 461 |
| NCT04008030Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Aug 28, 2024 | 839 |
| NCT03980314Melanoma · United States, Argentina, Australia and more | 1 | Completed | Bristol-Myers Squibb | Mar 4, 2021 | 261 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Aug 25, 2029 | 1,500 |
| NCT03770299Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Bristol-Myers Squibb | Mar 14, 2023 | 0 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Bristol-Myers Squibb | Feb 27, 2022 | 0 |
| NCT03668119Pan Tumor · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | May 3, 2022 | 212 |
| NCT03661320Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 16, 2026 | 855 |
| NCT03656718Neoplasms by Site · United States, Argentina, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Sep 7, 2022 | 139 |
| NCT03646123Hodgkin Disease · United States, Australia, Czechia and more | 2 | Terminated | Pfizer | Nov 7, 2022 | 255 |
| NCT03519256Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Terminated | Bristol-Myers Squibb | Aug 22, 2022 | 142 |
| NCT03444766Carcinoma, Non-Small-Cell Lung · India | 4 | Completed | Bristol-Myers Squibb | Jul 17, 2019 | 100 |
| NCT03414983Colorectal Neoplasms · United States, Canada, Japan and more | 3 | Completed | Bristol-Myers Squibb | Feb 1, 2021 | 196 |
| NCT03383458Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | May 27, 2026 | 545 |
| NCT03377361Colorectal Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Nov 4, 2024 | 325 |
| NCT03371992Carcinoma, Non-Small-Cell Lung · United States | Early 1 | UNKNOWN | nilogen-oncosystems | Dec 2020 | 25 |
| NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more | 3 | Completed | Bristol-Myers Squibb | Oct 14, 2019 | 74 |
| NCT03338790Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Jan 13, 2021 | 292 |
| NCT03342417Ovarian Neoplasms · United States | 2 | Terminated | excellabio-llc | May 29, 2019 | 5 |
| NCT03215706Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Aug 16, 2019 | 719 |
| NCT03195491Lung Neoplasms · China, Thailand | 3 | Completed | Bristol-Myers Squibb | Jun 8, 2021 | 400 |
| NCT03195478Solid Tumor · China | 2 | Completed | Bristol-Myers Squibb | Jan 5, 2024 | 37 |
| NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 18, 2021 | 970 |
| NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 12, 2020 | 701 |
| NCT03138512Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Sep 28, 2023 | 1,641 |
| NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico | 3 | Terminated | Bristol-Myers Squibb | Feb 22, 2021 | 23 |
| NCT03117049Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Taiwan | 3 | Completed | Ono Pharmaceutical | Feb 10, 2020 | 550 |
| NCT03130959Various Advanced Cancer · United States, Australia, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Mar 10, 2020 | 166 |
| NCT03098550Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Jul 6, 2020 | 105 |
How it is read
Names in the registry
- “Nivolumab”, 115 entries
- “nivolumab”, 18 entries
- “ONO-4538”, 13 entries
- “BMS-936558 (MDX-1106)”, 5 entries
- “Nivolumab + Relatlimab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 36 studies
- Melanoma, 21 studies
- Carcinoma, Renal Cell, 11 studies
- Carcinoma, Hepatocellular, 6 studies
- Colorectal Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.